Conclusively, GPR30 appears to be a promising target for endocrine therapy, as blocking GPR30 signaling would be an important supplement in endocrine therapy and a strategy to overcome the resistance to endocrine therapy in patients with ERα+ and GPR30+ breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.